body weight less or equal to 100 kg who received 45 mg. Additionally, PASI responses from ACCEPT between ustekinumab and etanercept were used. Costs in the model included drug acquisition costs only. RESULTS: In the weight-based efficacy analysis, ustekinumab 45 mg treatment had the highest PASI 75 response. Under a fixed budget of $75,000/TL 1,000, it is possible to treat more patients successfully (achieving a PASI75) with ustekinumab 45 mg than with etanercept 50 mg biweekly. In both the first year of therapy and in the maintenance year, ustekinumab 45 mg is more cost-effective compared to etanercept 50 mg biweekly. CONCLUSIONS: According to the results of the cost per responder model, ustekinumab 45 mg is more cost-effective than etanercept 50 mg biweekly and therefore a preferable alternative in the treatment of moderate to severe plaque psoriasis in Turkey.

EFFICIENCY (COST/EFFICACY) OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
Losero P1, Blasco AJ2, Ferrándiz C3, Garcia A4, Isla J5
1Acute Dermatology Unit, Hospital Universitario de la Princesa (HUP), TSS, Madrid, Spain, 2Universidad Autónoma de Barcelona, Badalona, Barcelona, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Complejo Hospitalario de Badajoz, Badajoz, Spain
OBJECTIVES: To estimate the cost/efficacy ratios of biologics authorized in Spain in 2009 (adalimumab, etanercept, infliximab and ustekinumab) in the management of moderate-severe psoriasis. METHOD: A model for economic decision (decision tree) was built for the treatments according to the available scientific evidence. The payer perspective (National Health System) was used, only considering drug cost and assuming zero cost for placebo. In the case of weight-dependent dosing, the weight of the patient was adjusted by age and sex using the standard Spanish population. The cost of physician visits and lab was inflated to 2009 from 2006 Medicare clinical laboratory fee schedule and physician reimbursement schedule (which used mean US wholesale acquisition cost (WAC) was used for calculating costs. The analyses used deterministic sensitivity analysis building scenarios with the confidence intervals at 95% for costs and efficacy. RESULTS: The incremental efficacy in the baseline scenario ranged from 31.19 % (etanercept; 25 mg twice a week at 12 weeks of treatment) to 78.34% (infliximab: 5 mg/kg at 24 weeks of treatment). The efficiency in terms of cost/efficacy, in the baseline scenario, ranged from €88,013 (adalimumab at 16 weeks) and €17,981 (ustekinumab: 90 mg at 12 weeks) per PASI 75 responder. In the sensitivity analysis, adalimumab remains as the most efficacious biologic on the most and least favourable scenarios. CONCLUSIONS: Of the biologic agents authorized in Spain for treating moderate-severe psoriasis, the most efficent in terms of cost/efficacy is adalimumab.

COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL
Feldman SR, Augustin M, Martin S, Stanpoy M, Schaal B
Wake Forest University, Winston-Salem, NC, USA, 2University Clinics of Hamburg, Hamburg, Germany, 3Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 4Centocor Research & Development, Inc, Malvern, PA, USA
OBJECTIVES: To compare the cost per responder of ustekinumab (UST) versus etanercept (ETN) based on head-to-head data from the ACCEPT trial, which demonstrated greater efficacy of two doses of UST, 45 mg and 90 mg at weeks 0 and 4, versus ETN, 50 mg twice weekly through week 12, in patients with moderate-to-severe plaque psoriasis (PsO). METHODS: Efficacy results (proportion of patients achieving at least 75% improvement in the Psoriasis Area and Severity Index [PASI75]) were obtained from the ACCEPT trial (n = 903). Given the unique dosing of UST (weeks 0, 4, 16, and q12 weeks thereafter), we determined the cost per PASI75 response at week 16, the appropriate decision point for determining whether to proceed with a third dose. Week 16 PASI75 results were assumed to be equal to week 12 efficacy from ACCEPT; previously published randomized controlled trials have reported similar observations for both drugs. Dosing through week 12 was per ACCEPT. Dosing for weeks 13–16 was assumed to be per labeled indication in PsO. RESULTS: In ACCEPT, 209 patients received UST 45 mg, 347 received UST 90 mg, and 347 were randomized to ETN. The probabilities of treatment response were taken from the ACCEPT trial (which compared both the drugs); while utility values for different stages were obtained from published studies. A 12 week paradigm for the base case of each agent was developed on the basis of dosage administration, laboratory monitoring utilized in the Randomized Clinical Trials and manufacturer’s published guidelines. The cost of therapies included 2009 AWP (average wholesale price) of both the drugs, and cost of physician visits and lab were inflated to 2009 from 2006 Medicare clinical laboratory fee schedule and physician reimbursement schedule (which used mean US reimbursement). Since the time frame of the analysis was only 12 weeks, the costs of long-term side effects and adverse events were not included. Extrapolations were made to evaluate the cost-effectiveness of two drugs over a period of five years, with costs and benefits discounted at 3.3% per annum. Various sensitivity analysis were carried out to test the robustness of the model. RESULTS: The QALYs gained by Ustekinumab in comparison to Etanercept over a period of 5 years were 0.23, at an incremental cost-effectiveness ratio (ICER) of $65,693.59 per QALY gained. Further sensitivity analysis confirmed the robustness of results. CONCLUSIONS: Although as per the present analysis, Ustekinumab might not appear to be more cost effective than Etanercept, but it may be recommended due to modest increase in QALYs and convenient dosage pattern of once in 12 weeks.

Validity and Reliability of the Visual Function Questionnaire Utility Index in Individuals with Age-related Macular Degeneration
Stevens K1, Patrick D2, Kawasaki J3, Sullivan S4
1University of Washington, Seattle, WA, USA, 2Allergan, Irvine, CA, USA
OBJECTIVES: The Visual Function Questionnaire Utility Index (VFQ-UI) is a vision-specific, preference measure developed from the National Eye Institute Visual Function Questionnaire 25. (NEI VFQ-25). The objective of this analysis was to assess the validity and reliability of the VFQ-UI in individuals with age-related macular degeneration (AMD). METHODS: Post-hoc analysis using data collected from a multicenter, randomized controlled trial of 138 individuals with AMD. The NEI VFQ-25, HUI and EQ-SD were administered at baseline and day 1, day 14 and day 18. The NEI VFQ-25 dataset was used to calculate utility values using the VFQ-UI algorithm. Validity was assessed using convergent validity with HUI2, HUI3 and visual acuity and discriminant validity with the EQ-SD and known groups of visual acuity. Reliability was...